CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.
  
  OVERVIEW OF ACTIVITY
  Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.
  
  These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across acute leukemias, breast cancer, gastrointestinal cancers, genitourinary cancers, lung cancer, lymphomas and chronic lymphocytic leukemia and ovarian cancer to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Al B Benson III, MD
  Professor of Medicine
  Associate Director for Clinical Investigations
  Robert H Lurie Comprehensive Cancer Center of Northwestern University
  Chicago, Illinois
  
  Advisory Committee: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Genentech, Guardant Health, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Merck Sharp & Dohme Corp, Novartis, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Infinity Pharmaceuticals Inc.
  
  Harold J Burstein, MD, PhD
  Associate Professor of Medicine
  Harvard Medical School
  Breast Oncology Center
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  

  No relevant conflicts of interest to disclose.
  
  Don S Dizon, MD
  Director, Women’s Cancers
  Founder, Sexual Health First Responders Clinic
  Lifespan Cancer Institute
  Director of Medical Oncology, Rhode Island Hospital
  Associate Professor of Medicine, Alpert Medical School of Brown University
  Providence, Rhode Island
  
  Contracted Research: Bristol-Myers Squibb Company; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc.
  
  Howard S Hochster, MD
  Associate Director (Clinical Research)
  Yale Cancer Center
  Professor of Medicine
  Yale School of Medicine
  New Haven, Connecticut
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech; Data and Safety Monitoring Board/Committee: Genentech, Pfizer Inc.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  St Louis, Missouri
  
  Consulting Agreements: Celgene Corporation, Genentech, Pharmacyclics LLC, an AbbVie Company.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Vice Chair, Radiation Therapy Oncology Group
  Philadelphia, Pennsylvania
  
  Advisory Committee: AbbVie Inc, Ariad Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Lilly, Merck, Pfizer Inc, Takeda Oncology; Consulting Agreements: Bayer HealthCare Pharmaceuticals, BeiGene, Genentech, Guardant Health, Lilly, Merck, Novocure; Contracted Research: Advantagene Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc, Incyte Corporation, Lilly, SWOG.
  
  Frederick L Locke, MD
  Program Co-Leader, Immunology
  Moffitt Cancer Center
  Tampa, Florida
  
  Advisory Committee: Gilead Sciences Inc, Kite Pharma Inc, Novartis; Consulting Agreement: Cellular Biomedicine Group Inc.
  
  Peter H O’Donnell, MD
  Assistant Professor, Department of Medicine
  Section of Hematology/Oncology
  Genitourinary Oncology Program
  The University of Chicago
  Chicago, Illinois
  
  Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP/MedImmune Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, Janssen Biotech Inc, Merck, Seattle Genetics; Expert Testimony: Temple Health, Trinity Health; Honoraria: Algeta ASA, American Medical Forum, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Genentech, Harrison Consulting, Inovio Pharmaceuticals Inc, Janssen Biotech Inc, Kantar Health, Merck, Novartis, PAREXEL International Corporation, Quintiles, Seattle Genetics, Xcenda; Stock: Allergan Inc; Travel: Merck.
  
  David M O’Malley, MD
  Professor
  Director, Clinical Research, Gynecologic Oncology
  Co-Director, Gynecologic Oncology Phase I Program
  ORIEN Physician Liaison for OSUCCC – James
  The Ohio State University and The James Cancer Center
  Columbus, Ohio
  
  Advisory Committee: Amgen Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.
  
  Geoffrey R Oxnard, MD
  Lowe Center for Thoracic Oncology
  Dana-Farber Cancer Institute
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, DropWorks CEI, GRAIL Inc, Guardant Health, Ignyta Inc, Inivata, Loxo Oncology.
  
  Hope S Rugo, MD
  Professor of Medicine
  Director, Breast Oncology and Clinical Trials Education
  University of California, San Francisco
  Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  Contracted Research: Eisai Inc, Genentech, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Plexxikon Inc, Roche Laboratories Inc; Paid Travel: Lilly, Mylan NV, Puma Biotechnology Inc.
  
  Guru Sonpavde, MD
  Bladder Cancer Director
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, EMD Serono Inc, Genentech, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Pfizer Inc, Sanofi Genzyme; Data and Safety Monitoring Board/Committee: Boehringer Ingelheim Pharmaceuticals Inc; Other Remunerated Activities: Author of UpToDate.
  
  Eytan M Stein, MD
  Hematologist and Medical Oncologist
  Assistant Attending Physician
  Leukemia Service
  Department of Medicine
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Agios Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, Pfizer Inc.
  
  Stacey Stein, MD
  Assistant Professor of Medicine (Medical Oncology)
  Yale Cancer Center
  New Haven, Connecticut
  
  Advisory Committee: Eisai Inc, Genentech, Merck.
  
  Richard M Stone, MD
  Director, Adult Leukemia Program
  Dana-Farber Cancer Institute
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, Actinium Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Amgen Inc, Argenx, Arog Pharmaceuticals Inc, Astellas Pharma Global Development Inc, Celator Pharmaceuticals Inc, Celgene Corporation, FUJIFILM Pharmaceuticals USA Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Juno Therapeutics, Karyopharm Therapeutics, Merck, Novartis, Orsenix, Otsuka America Pharmaceutical Inc, Pfizer Inc, Rafael Pharmaceuticals Inc, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Novartis.
  
  Michael E Williams, MD, ScM
  Byrd S Leavell Professor of Medicine
  Chief, Hematology/Oncology Division
  University of Virginia School of Medicine
  Charlottesville, Virginia
  
  Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Novartis, TG Therapeutics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech, Genomic Health Inc, Guardant Health, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics, Taiho Oncology Inc and Tesaro Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: December 2018
  Expiration date: December 2019